These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Modifications of an immunodominant peptide antigen induce different anti-polyoma tumor responses in two separate mouse strains. Author: Reinholdsson-Ljunggren G, Dalianis T. Journal: Int J Cancer; 1992 Jul 30; 51(6):968-72. PubMed ID: 1322381. Abstract: An immunodominant polyoma peptide antigen MT162-176 was modified with regard to amino acid (aa) composition in an attempt to analyze its immunogenicity in detail. Twelve modifications of peptide MT162-176, 3 overlapping peptides and 9 peptides with point mutations, were synthesized and used for immunizations of (A.CA x C57BL/6)F1 and CBA mice against the syngeneic polyoma tumors SECA and SEBA. All 3 overlapping peptides MT162-176, MT165-174 and MT170-176, were immunogenic in (A.CA x C57BL/6)F1 mice against SECA, indicating that possibly more than one immunogenic epitope may be recognized within the MT162-176 sequence. In CBA mice, the 2 peptides covering the C-terminal half were immunogenic against SEBA, while the N-terminal peptide was possibly somewhat less efficient. The peptides with aa point mutations induced different anti-tumor responses in the 2 mouse strains. In CBA mice, only one mutant, MT162-176.28, was immunogenic. For (A.CA x C57BI)F1 3 different mutants, MT162-176.29, MT162-176.35 and MT162-176.36 were immunogenic against SECA, while the remaining 6 had lost their activity. These results suggest that a different emphasis of recognition of peptide MT162-176 exists with regard to the 2 mouse strains examined. Furthermore, different immunization procedures were tested. We found that repeated immunizations with peptide without Freund's adjuvant was the most efficient.[Abstract] [Full Text] [Related] [New Search]